Literature DB >> 21837794

High prevalence of BK polyomavirus sequences in human papillomavirus-16-positive precancerous cervical lesions.

Manola Comar1, Daniela Bonifacio, Fabrizio Zanconati, Michela Di Napoli, Erica Isidoro, Fernanda Martini, Lucio Torelli, Mauro Tognon.   

Abstract

High- and low-grade cervical lesions were analyzed for the presence of polyomavirus (PYV) and human papillomavirus (HPV) sequences. In precancerous cervical lesions, the overall prevalence of PYV sequences was 44% (41/93). Specifically, among the PYV-positive samples, 83% (34/41) tested positive for BK polyomavirus (BKV) sequences, whereas 17% (7/41) were positive for JC-virus. None of the samples were positive for simian virus 40. The presence of BKV DNA in high-grade squamous intraepithelial lesions was confirmed by in situ PCR. BKV sequences were detected more frequently in high-grade squamous intraepithelial lesions, together with the genotype HPV-16. The association of BKV with precancerous cervical lesions suggests that this polyomavirus participates with HPV-16 in the cell transformation process. Alternatively, BKV might multiply better in HPV-16-positive cells from precancerous cervical lesions than in HPV-16-negative cells.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21837794     DOI: 10.1002/jmv.22184

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

Review 1.  The interaction between human papillomavirus and other viruses.

Authors:  J T Guidry; R S Scott
Journal:  Virus Res       Date:  2016-11-05       Impact factor: 3.303

2.  Coinfection with Epstein-Barr Virus (EBV), Human Papilloma Virus (HPV) and Polyoma BK Virus (BKPyV) in Laryngeal, Oropharyngeal and Oral Cavity Cancer.

Authors:  Bartłomiej Drop; Małgorzata Strycharz-Dudziak; Ewa Kliszczewska; Małgorzata Polz-Dacewicz
Journal:  Int J Mol Sci       Date:  2017-12-19       Impact factor: 5.923

3.  Polyomaviruses detectable in head and neck carcinomas.

Authors:  Leonard Poluschkin; Jaana Rautava; Aaro Turunen; Yilin Wang; Klaus Hedman; Kari Syrjänen; Reidar Grenman; Stina Syrjänen
Journal:  Oncotarget       Date:  2018-04-27

4.  Simultaneous Detection and Viral DNA Load Quantification of Different Human Papillomavirus Types in Clinical Specimens by the High Analytical Droplet Digital PCR Method.

Authors:  John Charles Rotondo; Lucia Oton-Gonzalez; Chiara Mazziotta; Carmen Lanzillotti; Maria Rosa Iaquinta; Mauro Tognon; Fernanda Martini
Journal:  Front Microbiol       Date:  2020-11-19       Impact factor: 5.640

Review 5.  Emerging role of human polyomaviruses 6 and 7 in human cancers.

Authors:  Ghalib Mobaraki; Dan Liu; Faisal Klufah; Raed A Alharbi; Anna Kordelia Kurz; Ernst Jan M Speel; Véronique Winnepenninckx; Axel Zur Hausen
Journal:  Infect Agent Cancer       Date:  2021-05-17       Impact factor: 2.965

6.  Human Virome in Cervix Controlled by the Domination of Human Papillomavirus.

Authors:  Thanayod Sasivimolrattana; Wasun Chantratita; Insee Sensorn; Arkom Chaiwongkot; Shina Oranratanaphan; Parvapan Bhattarakosol
Journal:  Viruses       Date:  2022-09-17       Impact factor: 5.818

7.  Association between the JC polyomavirus infection and male infertility.

Authors:  Manola Comar; Nunzia Zanotta; Eleonora Croci; Immacolata Murru; Roberto Marci; Cecilia Pancaldi; Ornella Dolcet; Stefania Luppi; Monica Martinelli; Elena Giolo; Giuseppe Ricci; Mauro Tognon
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

Review 8.  Role of BK human polyomavirus in cancer.

Authors:  Jorge Levican; Mónica Acevedo; Oscar León; Aldo Gaggero; Francisco Aguayo
Journal:  Infect Agent Cancer       Date:  2018-04-05       Impact factor: 2.965

9.  Reciprocal transactivation of Merkel cell polyomavirus and high-risk human papillomavirus promoter activities and increased expression of their oncoproteins.

Authors:  Kashif Rasheed; Baldur Sveinbjørnsson; Ugo Moens
Journal:  Virol J       Date:  2021-07-03       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.